Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity

Douglas E. Brenneman, Janet M. Hauser, Catherine Y. Spong, Terry M. Phillips

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The envelope protein (gp120) of the human immunodeficiency virus produces neuronal cell death in cultures that can be prevented by co-treatment with pituitary adenylate activating peptide-38 (PACAP-38) or chemokines. To investigate the hypothesis that a functional relationship exists between these two protectants, the release of chemokines was measured in rat astrocyte cultures after PACAP-38 treatment. Chemokine analyses were performed by immunoaffinity capillary electrophoresis. Bell-shaped dose-responses for PACAP-mediated release of chemokines into the culture medium were observed with EC50's of 3 x 1015 M (RANTES: regulated upon activation normal T cell expressed and secreted), 3 x 10-11 M (MIP-1β) and 10-7 M (MIP-1α). In addition, PACAP-mediated depletion of chemokines from cultured astrocytes exhibited inverted bell-shaped curves, with similar EC50's to those observed for chemokine measurements of the medium. Comparative studies with structurally related peptides (vasoactive intestinal peptide [VIP] and secretin) revealed that PACAP was the most potent secretagogue for RANTES on astrocyte cultures. Gp120-mediated neuronal cell death was prevented by co-treatment with PACAP-38, although the efficacy of protection varied significantly among the gp120 isolates. A bi-model dose-response was observed with EC50's of 3 x 10-15 and 3 x 10-11 M. Co-treatment with neutralizing antiserum to RANTES attenuated PACAP-mediated protection from toxicity associated with gp120. In contrast to previous studies with VIP and gp120 toxicity, co-treatment with anti-MIP-1α did not affect PACAP-induced protection. These studies support the hypothesis that PACAP produces neuroprotection from gp120 toxicity, in part, through the release of RANTES and this mechanism is distinct from that observed with VIP.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalNeuropeptides
Volume36
Issue number4
DOIs
StatePublished - Aug 2002
Externally publishedYes

Fingerprint

Human Immunodeficiency Virus Proteins
Pituitary Adenylate Cyclase-Activating Polypeptide
Chemokines
Chemokine CCL5
Peptides
Vasoactive Intestinal Peptide
Astrocytes
Human Immunodeficiency Virus env Gene Products
Cell Death
Secretin
Capillary Electrophoresis
Culture Media
Immune Sera
T-Lymphocytes

ASJC Scopus subject areas

  • Endocrinology
  • Neurology
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity. / Brenneman, Douglas E.; Hauser, Janet M.; Spong, Catherine Y.; Phillips, Terry M.

In: Neuropeptides, Vol. 36, No. 4, 08.2002, p. 271-280.

Research output: Contribution to journalArticle

Brenneman, Douglas E. ; Hauser, Janet M. ; Spong, Catherine Y. ; Phillips, Terry M. / Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity. In: Neuropeptides. 2002 ; Vol. 36, No. 4. pp. 271-280.
@article{a9385aa93b624c37bf3988f653a50c22,
title = "Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity",
abstract = "The envelope protein (gp120) of the human immunodeficiency virus produces neuronal cell death in cultures that can be prevented by co-treatment with pituitary adenylate activating peptide-38 (PACAP-38) or chemokines. To investigate the hypothesis that a functional relationship exists between these two protectants, the release of chemokines was measured in rat astrocyte cultures after PACAP-38 treatment. Chemokine analyses were performed by immunoaffinity capillary electrophoresis. Bell-shaped dose-responses for PACAP-mediated release of chemokines into the culture medium were observed with EC50's of 3 x 1015 M (RANTES: regulated upon activation normal T cell expressed and secreted), 3 x 10-11 M (MIP-1β) and 10-7 M (MIP-1α). In addition, PACAP-mediated depletion of chemokines from cultured astrocytes exhibited inverted bell-shaped curves, with similar EC50's to those observed for chemokine measurements of the medium. Comparative studies with structurally related peptides (vasoactive intestinal peptide [VIP] and secretin) revealed that PACAP was the most potent secretagogue for RANTES on astrocyte cultures. Gp120-mediated neuronal cell death was prevented by co-treatment with PACAP-38, although the efficacy of protection varied significantly among the gp120 isolates. A bi-model dose-response was observed with EC50's of 3 x 10-15 and 3 x 10-11 M. Co-treatment with neutralizing antiserum to RANTES attenuated PACAP-mediated protection from toxicity associated with gp120. In contrast to previous studies with VIP and gp120 toxicity, co-treatment with anti-MIP-1α did not affect PACAP-induced protection. These studies support the hypothesis that PACAP produces neuroprotection from gp120 toxicity, in part, through the release of RANTES and this mechanism is distinct from that observed with VIP.",
author = "Brenneman, {Douglas E.} and Hauser, {Janet M.} and Spong, {Catherine Y.} and Phillips, {Terry M.}",
year = "2002",
month = "8",
doi = "10.1016/S0143-4179(02)00045-8",
language = "English (US)",
volume = "36",
pages = "271--280",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity

AU - Brenneman, Douglas E.

AU - Hauser, Janet M.

AU - Spong, Catherine Y.

AU - Phillips, Terry M.

PY - 2002/8

Y1 - 2002/8

N2 - The envelope protein (gp120) of the human immunodeficiency virus produces neuronal cell death in cultures that can be prevented by co-treatment with pituitary adenylate activating peptide-38 (PACAP-38) or chemokines. To investigate the hypothesis that a functional relationship exists between these two protectants, the release of chemokines was measured in rat astrocyte cultures after PACAP-38 treatment. Chemokine analyses were performed by immunoaffinity capillary electrophoresis. Bell-shaped dose-responses for PACAP-mediated release of chemokines into the culture medium were observed with EC50's of 3 x 1015 M (RANTES: regulated upon activation normal T cell expressed and secreted), 3 x 10-11 M (MIP-1β) and 10-7 M (MIP-1α). In addition, PACAP-mediated depletion of chemokines from cultured astrocytes exhibited inverted bell-shaped curves, with similar EC50's to those observed for chemokine measurements of the medium. Comparative studies with structurally related peptides (vasoactive intestinal peptide [VIP] and secretin) revealed that PACAP was the most potent secretagogue for RANTES on astrocyte cultures. Gp120-mediated neuronal cell death was prevented by co-treatment with PACAP-38, although the efficacy of protection varied significantly among the gp120 isolates. A bi-model dose-response was observed with EC50's of 3 x 10-15 and 3 x 10-11 M. Co-treatment with neutralizing antiserum to RANTES attenuated PACAP-mediated protection from toxicity associated with gp120. In contrast to previous studies with VIP and gp120 toxicity, co-treatment with anti-MIP-1α did not affect PACAP-induced protection. These studies support the hypothesis that PACAP produces neuroprotection from gp120 toxicity, in part, through the release of RANTES and this mechanism is distinct from that observed with VIP.

AB - The envelope protein (gp120) of the human immunodeficiency virus produces neuronal cell death in cultures that can be prevented by co-treatment with pituitary adenylate activating peptide-38 (PACAP-38) or chemokines. To investigate the hypothesis that a functional relationship exists between these two protectants, the release of chemokines was measured in rat astrocyte cultures after PACAP-38 treatment. Chemokine analyses were performed by immunoaffinity capillary electrophoresis. Bell-shaped dose-responses for PACAP-mediated release of chemokines into the culture medium were observed with EC50's of 3 x 1015 M (RANTES: regulated upon activation normal T cell expressed and secreted), 3 x 10-11 M (MIP-1β) and 10-7 M (MIP-1α). In addition, PACAP-mediated depletion of chemokines from cultured astrocytes exhibited inverted bell-shaped curves, with similar EC50's to those observed for chemokine measurements of the medium. Comparative studies with structurally related peptides (vasoactive intestinal peptide [VIP] and secretin) revealed that PACAP was the most potent secretagogue for RANTES on astrocyte cultures. Gp120-mediated neuronal cell death was prevented by co-treatment with PACAP-38, although the efficacy of protection varied significantly among the gp120 isolates. A bi-model dose-response was observed with EC50's of 3 x 10-15 and 3 x 10-11 M. Co-treatment with neutralizing antiserum to RANTES attenuated PACAP-mediated protection from toxicity associated with gp120. In contrast to previous studies with VIP and gp120 toxicity, co-treatment with anti-MIP-1α did not affect PACAP-induced protection. These studies support the hypothesis that PACAP produces neuroprotection from gp120 toxicity, in part, through the release of RANTES and this mechanism is distinct from that observed with VIP.

UR - http://www.scopus.com/inward/record.url?scp=0036700820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036700820&partnerID=8YFLogxK

U2 - 10.1016/S0143-4179(02)00045-8

DO - 10.1016/S0143-4179(02)00045-8

M3 - Article

C2 - 12372701

AN - SCOPUS:0036700820

VL - 36

SP - 271

EP - 280

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 4

ER -